Two recent papers attach GHK, or GHK-Cu, to silver nanoparticles and test the result on wounds. The pitch is attractive: silver kills bacteria, the peptide supports healing, and a particle that does both could treat an infected wound. The papers deserve a close look, because for the antibacterial part of the claim the silver is the active ingredient.
One paper tested bacteria, cell toxicity and infected wounds in animals[1]. The other tested only the effect on cultured fibroblasts, and it is open about that[2].
Key Takeaways
- In the 2024 paper, GHK- and GHK-Cu-modified silver particles stopped the growth of S. aureus and E. coli at 8 micrograms per milliliter[1].
- The concentration that cut viability of the L929 cells it was tested on by half (the IC50) was 6.75 to 6.99 micrograms per milliliter, slightly below the bacterial one[1].
- The antibacterial action most likely comes from the silver. The abstract reports no antibacterial test of the peptide alone[1].
- The 2023 paper found that peptide-silver conjugates closed a scratch in cultured mouse fibroblasts better than either part alone. It did no animal or bacterial work[2].
The Idea Behind the Particles
Silver nanoparticles are widely used as antimicrobial agents. Their high toxicity limits how they can be used, which is the problem the 2024 authors set out to address[1]. The authors describe an urgent need for simple, efficient ways to treat bacterial infections and promote wound healing, and they built the particles to do both[1].
The peptide in both papers is GHK. In this context the copper question matters, because the authors made two versions: one coated with GHK and one coated with the copper complex, GHK-Cu[1]. The 2023 paper used the copper complex, which it calls copper tripeptide 1 and describes as the complex of glycyl-L-histidyl-L-lysine with copper[2].
What the 2024 Paper Reports
The particles were spherical, with average sizes of 45.92 nanometers for the GHK version and 56.82 nanometers for the GHK-Cu version, in the order the abstract lists them[1]. The authors tested them against four pathogenic bacterial isolates.
The minimum inhibitory concentration, the lowest amount that stopped visible growth, was 8 micrograms per milliliter against Staphylococcus aureus and Escherichia coli[1]. The abstract also reports superior bactericidal effects against S. aureus, with complete inhibition after seven days of treatment, without saying superior to what[1].
The wound experiments came next. In cultured cells, the GHK version accelerated cell migration and facilitated healing of up to 92% after 12 hours, as the abstract puts it[1]. When applied to the skin of animals with S. aureus-infected wounds, both versions improved healing compared with control groups. The healing showed up as thicker regenerated epidermis, better collagen deposition and lower expression of the inflammatory signal TNF-alpha[1].
The Two Numbers That Sit Close Together
The most important detail in the abstract is a pair of figures. The antibacterial concentration was 8 micrograms per milliliter. The concentration that halved cell viability in the L929 cell line, the half-maximal inhibitory concentration or IC50, was 6.75 to 6.99 micrograms per milliliter[1].
Put side by side, the amount needed to stop the bacteria is about 1.1 to 1.2 times the amount that cuts cell viability in half. In other words, in this cell-culture comparison there was no gap between the antibacterial dose and the toxic one. The toxic concentration is, if anything, slightly lower.
That does not mean the particles would poison a wound. A wound is not a dish of cells, and the abstract does not give the exposure times of the two assays, or say whether both figures are expressed on the same basis. Even so, the proximity is the reason the authors’ framing, an antibacterial that also heals, needs the animal data to carry weight.
It also echoes the problem the paper starts with. Silver nanoparticles are used for their antimicrobial effect, and their toxicity limits their use[1]. The abstract gives no figures for unmodified particles, so it is not possible to say whether adding the peptide changed that limit.
Who Is Doing the Killing
The abstract does not report a bacterial test of GHK or GHK-Cu on its own, and it does not say whether unmodified silver particles were included as a comparison[1]. Without those arms, the experiment cannot tell you how much the peptide adds to the antibacterial result.
Silver nanoparticles are antimicrobial by themselves. That is the premise of the field the paper sits in[1]. So the most direct reading is that the antibacterial effect comes from the silver, and the peptide is presumably there for its effect on cells and tissue.
That reading matters for anyone who has seen GHK-Cu described as antibacterial. The site’s page on the antimicrobial evidence for GHK-Cu sets out what has been tested on the peptide itself. A silver-coated particle cannot be used as evidence for the peptide in that debate.
The 2023 Fibroblast Study
The second paper made two peptide-silver conjugates, one with copper tripeptide 1 and one with a different peptide, myristoyl tetrapeptide 6. It also made plain silver particles as a control[2]. The peptide was added either while the silver was formed or afterward, and the order changed how well the synthesis worked and what the particles looked like[2].
The test was a scratch assay. A line was scraped across a layer of NIH/3T3 mouse embryo fibroblasts, the cells were kept in serum-free medium for 48 hours beforehand to arrest proliferation, and the closure of the gap was photographed at 24 and 48 hours[2].
At 24 hours the copper-tripeptide conjugate closed 62.37% of the scratch, with a standard deviation of 18.33 points. The free copper peptide closed 22.08%, and plain silver particles closed 29.53%[2]. The conjugate was 2.82 times better than the free peptide, with p below 0.05[2]. The free peptides did not differ significantly from the positive control[2].
Two cautions apply. The spread around the conjugate result is wide for a mean of 62%, which the reported standard deviation makes plain. And the authors state their main limitation outright: the findings come from in vitro observations, and future studies are needed before any efficacy testing at a clinical level[2]. The paper reports no external funding and no relevant conflict of interest[2].
What Each Paper Can and Cannot Support
The 2024 paper supports a narrow claim. Silver nanoparticles modified with GHK or GHK-Cu were antibacterial in the laboratory at a concentration close to their cell-toxic one, and helped infected wounds in an animal model heal better than whatever the control groups received[1]. Because the abstract does not say what those controls were, a reader cannot tell how much of the benefit came from the peptide.
The 2023 paper supports an even narrower one. A peptide-silver conjugate moved fibroblasts across a scratch in a dish faster than either part alone, in one cell line and one assay[2]. It says nothing about bacteria, wounds in animals or people.
Neither paper involved a person. The animal data come from an abstract that omits the species, the group sizes and the doses.
What This Means for a Reader
These are materials-science papers about a possible wound dressing ingredient. They are not evidence for a GHK-Cu serum, which is a different product. They also do not suggest that GHK-Cu on its own kills bacteria in a wound.
If you want the broader wound-healing picture for the peptide, the page on GHK-Cu and wound healing covers it, and the page on diabetic wound healing covers the specific model where infection and slow healing meet. An infected wound is a medical problem, and a clinician is the right person to assess it.
Frequently Asked Questions
Is GHK-Cu antibacterial because of silver nanoparticle studies?
No. The abstract reports no antibacterial test of the peptide alone, and silver nanoparticles are widely used as antimicrobials, so the most direct reading is that the silver did the killing. The result cannot be used as evidence that GHK-Cu itself kills bacteria.
What concentration stopped bacteria in the silver nanoparticle study?
A minimum inhibitory concentration of 8 micrograms per milliliter against Staphylococcus aureus and Escherichia coli, for both the GHK and GHK-Cu versions.
How toxic were the particles to cells?
The IC50, the concentration that halved cell viability in L929 cells, was 6.75 to 6.99 micrograms per milliliter. That sits just below the 8 micrograms per milliliter needed to stop the bacteria, so there was no gap between the two in culture.
Were the wound results tested in people?
No. The 2024 paper used an animal model of infected wounds, and the 2023 paper used only cultured fibroblasts. Neither involved a person.
What did the copper tripeptide silver particles do to fibroblasts?
In a scratch assay on NIH/3T3 mouse fibroblasts, the conjugate closed about 62% of the gap at 24 hours, compared with about 22% for the free copper peptide and about 30% for plain silver particles, with wide variation around the conjugate result.
Does a GHK-Cu serum contain silver nanoparticles?
These papers describe experimental materials for wound care, not skincare products. Nothing in them applies to a GHK-Cu serum.
References
- Islam R, et al. Tripeptides Ghk and GhkCu-modified silver nanoparticles for enhanced antibacterial and wound healing activities. Colloids and Surfaces. B, Biointerfaces (2024). PMID 38387323
- Papaioannou A, et al. Effect of Peptides on the Synthesis, Properties and Wound Healing Capacity of Silver Nanoparticles. Pharmaceutics (2023). PMID 37896231
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.


